Assessment of Chemotherapy Response of Malignant Sarcomas in Pediatric Patients with 18F-FDG PET/CT
| Study | Type of disease | Patients (n) | Timing of PET/CT | Parameter | Sensitivity | Specificity | PPV | NPV |
| Im (94) | OS | 20 | Interim | SUVmax | 100% | 88.9% | 83.3% | 100% |
| MTV | 100% | 88.9% | 83.3% | 100% | ||||
| TLG | 100% | 88.9% | 83.3% | 100% | ||||
| Therapy response | SUVmax | 100% | 88.9% | 83.3% | 100% | |||
| MTV | 60% | 100% | 100% | 81.8% | ||||
| TLG | 100% | 77.8% | 71.4% | 100% | ||||
| Denecke (92) | OS | 27 | Therapy response | Posttherapy SUVmax | 80% | 100% | 100% | 86% |
| ΔSUVmax | 100% | 83% | 83% | 100% | ||||
| Visual interpretation | 100% | 100% | 100% | 100% | ||||
| ESFT | Therapy response | Posttherapy SUVmax | 100% | 50% | 85% | 100% | ||
| ΔSUVmax | 91% | 50% | 83% | 67% | ||||
| Visual interpretation | 100% | 25% | 79% | 100% |
PPV = positive predictive value; NPV = negative predictive value; OS = osteosarcoma; MTV = metabolic tumor volume; TLG = total lesion glycolysis; ESFT = Ewing sarcoma family tumor; ΔSUVmax = reduction in posttherapy SUVmax compared with pretherapy SUVmax.